These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 6963044)

  • 21. Black mark for health care priorities.
    Halpern S
    Health Soc Serv J; 1980 Sep; 90(4709):1154. PubMed ID: 10248520
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessment of priorities when introducing some radiation protection methods in radiodiagnosis.
    Russell JG
    Br J Radiol; 1986 Feb; 59(698):153-6. PubMed ID: 3081072
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Social policy and chronic illness.
    Levine DE
    Health Soc Work; 1988; 13(2):83-4. PubMed ID: 3391439
    [No Abstract]   [Full Text] [Related]  

  • 24. [Medical research--money or life?].
    Fretheim A; Sørbye IK
    Tidsskr Nor Laegeforen; 2003 Oct; 123(20):2908-9. PubMed ID: 14600724
    [No Abstract]   [Full Text] [Related]  

  • 25. [Costs and options in tertiary gastroenterologic assistance].
    Vilardell F; Colell C
    Rev Esp Enferm Apar Dig; 1985 Feb; 67(2):177-9. PubMed ID: 3885348
    [No Abstract]   [Full Text] [Related]  

  • 26. Priority setting and economic appraisal: whose priorities--the community or the economist?
    Green A; Barker C
    Soc Sci Med; 1988; 26(9):919-29. PubMed ID: 3133778
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of state and local government in health. A federal perspective: an interview with Sen. David Durenberger.
    Durenberger D
    Health Aff (Millwood); 1983; 2(4):70-5. PubMed ID: 6674095
    [No Abstract]   [Full Text] [Related]  

  • 28. Priority review vouchers: an inefficient and dangerous way to promote neglected-disease drug development.
    Kesselheim AS
    Clin Pharmacol Ther; 2009 Jun; 85(6):573-5. PubMed ID: 19451908
    [No Abstract]   [Full Text] [Related]  

  • 29. Health planning as cost control device.
    Employee Benefit Plan Rev; 1977 Sep; 32(3):18. PubMed ID: 10304840
    [No Abstract]   [Full Text] [Related]  

  • 30. [Health policy and health economics. 5. Health system will have a more active role in the community].
    Filipsson AC
    Sygeplejersken; 1982 Dec; 82(47):20-2. PubMed ID: 6926287
    [No Abstract]   [Full Text] [Related]  

  • 31. Healthcare 'reform': deep cuts likely for Medicare providers.
    Gatty B
    Geriatrics; 1994 Sep; 49(9):54-6. PubMed ID: 8088560
    [No Abstract]   [Full Text] [Related]  

  • 32. Economic analysis in eye disease.
    Lee P; Zhang P
    Arch Ophthalmol; 2003 Jan; 121(1):115-6. PubMed ID: 12523895
    [No Abstract]   [Full Text] [Related]  

  • 33. What to look for in a managed eye care plan.
    Raycraft JA
    J Health Care Benefits; 1994; 4(1):62-4. PubMed ID: 10137549
    [No Abstract]   [Full Text] [Related]  

  • 34. [Prioritisation in the German health care system--an issue in ophthalmology?].
    Framme C; Helbig H; Preusker UK
    Klin Monbl Augenheilkd; 2009 Mar; 226(3):154-60. PubMed ID: 19294585
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Health, quality of live and money. Using cost-effectiveness analysis for setting health priorities].
    Benediktsdóttir B
    Laeknabladid; 2009 Nov; 95(11):743. PubMed ID: 19996461
    [No Abstract]   [Full Text] [Related]  

  • 36. The health care industry and the antitrust laws: on a collision course?
    Halper HR
    Mich Med; 1981 Sep; 80(26):473-8. PubMed ID: 7289889
    [No Abstract]   [Full Text] [Related]  

  • 37. [Increasing drug costs. The society's drug expenditures are strongly increasing. If this trend continues we have to make other priorities].
    Andreasen J
    Ugeskr Laeger; 2003 Jul; 165(29):2873-6. PubMed ID: 12908355
    [No Abstract]   [Full Text] [Related]  

  • 38. Changing health care practices. Three obligations.
    Bays KD
    Vital Speeches Day; 1986 Jan; 52(6):183-6. PubMed ID: 10275263
    [No Abstract]   [Full Text] [Related]  

  • 39. [Priorities by the board of drug benefits--guidelines clarify. Clinical trials are not sufficient for decisions on subsidizing].
    Carlsson P
    Lakartidningen; 2003 Jul; 100(30-31):2428-9. PubMed ID: 12914137
    [No Abstract]   [Full Text] [Related]  

  • 40. Health priorities for developing countries: importance of non-fatal but disabling conditions.
    Olusanya BO
    Trans R Soc Trop Med Hyg; 2006 Nov; 100(11):1089-90. PubMed ID: 16935315
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.